Circulating choline has been directly correlated with lung function in cystic fibrosis patients (28), and results of a pilot study in 10 patients suggested that choline supplementation may have utility in improving clinical outcomes in cystic fibrosis patients (29)
Choose high-quality, third-party tested brands Product quality makes a big difference in safety

Key findings from published and presented studies include: In a phase 2 obesity trial, higherdose retatrutide produced average weight loss of around 22.824.2% over 48 weeks in people with obesity. In participants with type 2 diabetes, retatrutide achieved substantial weight loss and marked improvements in blood sugar and cardiometabolic markers, though average percentage weight loss was somewhat lower than in nondiabetic obesity cohorts. Early studies also reported significant reductions in liver fat and visceral adipose tissue, with a high proportion of participants with fatty liver disease showing resolution of hepatic steatosis at higher doses. These results have led several reviews to describe retatrutide as a potential game changer in obesity pharmacotherapy, representing the first GLP1/GIP/glucagon triple agonist with robust human data. Popular coverage has highlighted phase 3 data suggesting average weight losses approaching 29% of body weight in some cohorts (roughly 71 pounds), which is about double typical results with semaglutide over comparable periods

While acute cortisol increases may be tolerable, protocols involving frequent or long-term administration would ideally avoid this confound
The article states that major clinical trials of semaglutide and tirzepatide have not identified depression as a common adverse effect